[go: up one dir, main page]

DE3776982D1 - Arzneimittel mit gesteuerter absorption. - Google Patents

Arzneimittel mit gesteuerter absorption.

Info

Publication number
DE3776982D1
DE3776982D1 DE8787305484T DE3776982T DE3776982D1 DE 3776982 D1 DE3776982 D1 DE 3776982D1 DE 8787305484 T DE8787305484 T DE 8787305484T DE 3776982 T DE3776982 T DE 3776982T DE 3776982 D1 DE3776982 D1 DE 3776982D1
Authority
DE
Germany
Prior art keywords
core
verapamil
polymeric material
powder mixture
controlled absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787305484T
Other languages
English (en)
Inventor
Edward James Geoghegan
Donald Eugene Panoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11030118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3776982(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of DE3776982D1 publication Critical patent/DE3776982D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8787305484T 1986-06-20 1987-06-19 Arzneimittel mit gesteuerter absorption. Expired - Lifetime DE3776982D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE166186A IE58401B1 (en) 1986-06-20 1986-06-20 Controlled absorption pharmaceutical composition

Publications (1)

Publication Number Publication Date
DE3776982D1 true DE3776982D1 (de) 1992-04-09

Family

ID=11030118

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787305484T Expired - Lifetime DE3776982D1 (de) 1986-06-20 1987-06-19 Arzneimittel mit gesteuerter absorption.

Country Status (10)

Country Link
US (1) US4863742A (de)
EP (1) EP0250267B1 (de)
JP (1) JP2637981B2 (de)
AT (1) ATE72975T1 (de)
AU (1) AU599385B2 (de)
DE (1) DE3776982D1 (de)
ES (1) ES2039440T3 (de)
GR (1) GR3003978T3 (de)
IE (1) IE58401B1 (de)
PH (1) PH23993A (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
PT88776B (pt) * 1987-10-16 1992-12-31 Elan Corp Limites Processo para a preparacao de formulacoes de diltiazem de absorcao controlada
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
JPH0791184B2 (ja) * 1988-03-31 1995-10-04 田辺製薬株式会社 放出制御型製剤およびその製法
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
CH678920A5 (de) * 1989-11-14 1991-11-29 Gergely Gerhard
JPH0463196A (ja) * 1990-06-30 1992-02-28 Kyodo:Kk 流体処理装置
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
IT1291652B1 (it) * 1997-04-24 1999-01-19 Apr Trading Sa Composizioni farmaceutiche a copertura terapeutica programmata
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
EP2266542A3 (de) * 1998-10-01 2013-07-31 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter Wirkstofffreisetzung
KR100574213B1 (ko) * 2000-01-27 2006-04-27 다나베 세이야꾸 가부시키가이샤 서방성 제제 및 그의 제조 방법
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1368000A4 (de) * 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co Chronotherapeutische dosierformen mit einem glucocorticosteroid
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
BR0206061A (pt) 2001-09-28 2004-01-13 Mcneil Ppc Inc Formas de dosagem que apresentam um núcleo interno e um invólucro externo com diferentes formas
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
AU2004268383A1 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
BRPI0414311A (pt) * 2003-09-19 2008-03-04 Penwest Pharmaceutical Co formas de dosagem de liberação controlada
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) * 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
WO2005077331A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
EP1768668A2 (de) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (de) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Geschmacksverdeckende pharmazeutische zusammensetzungen mit magenlöslichen porenbildnern
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
CA2628031C (en) 2005-11-10 2013-03-05 Circ Pharma Research And Development Limited Once-daily administration of central nervous system drugs
CA2640382C (en) * 2006-01-27 2015-12-29 Eurand, Inc Drug delivery systems comprising weakly basic drugs and organic acids
US20070190145A1 (en) * 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
JP2009545581A (ja) * 2006-08-04 2009-12-24 エイジーアイ・セラピューティクス・リサーチ・リミテッド Ｍｔ１受容体、５ｈｔ２ｂ受容体及びｌ型カルシウムチャンネル活性を有する少なくとも１つの状態の治療方法
EP3292866B1 (de) 2006-10-20 2023-07-26 Johnson & Johnson Consumer Inc. Acetaminophen/ibuprofen-kombinationen
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
MX2010003917A (es) 2007-10-12 2012-09-28 Takeda Pharmaceuticals Usa Inc Metodos de tratamiento de trastornos gastrointestinales independientemente de la ingesta alimenticia.
MX2010004897A (es) * 2007-10-31 2010-05-19 Mcneil Ppc Inc Forma de dosificacion oralmente desintegrada.
US8357395B2 (en) * 2007-12-21 2013-01-22 Mcneil-Ppc, Inc. Manufacture of tablet
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2009158368A1 (en) * 2008-06-26 2009-12-30 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
CN108159019A (zh) 2009-12-02 2018-06-15 阿黛尔药物有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
RU2712267C2 (ru) 2014-01-10 2020-01-28 Джонсон энд Джонсон Консьюмер Инк. Способ изготовления таблеток с использованием радиочастотного излучения и частиц с поглощающим покрытием
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3113901A1 (de) * 1981-04-07 1982-10-28 Basf Ag, 6700 Ludwigshafen Wirkstoffzubereitung zur oralen applikation
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
IE56151B1 (en) * 1983-10-20 1991-05-08 Elan Corp Plc Tablet formulation
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation

Also Published As

Publication number Publication date
GR3003978T3 (de) 1993-03-16
AU7452887A (en) 1987-12-24
EP0250267A2 (de) 1987-12-23
US4863742A (en) 1989-09-05
ATE72975T1 (de) 1992-03-15
JPS635021A (ja) 1988-01-11
AU599385B2 (en) 1990-07-19
JP2637981B2 (ja) 1997-08-06
ES2039440T3 (es) 1993-10-01
EP0250267A3 (en) 1988-08-10
IE58401B1 (en) 1993-09-08
PH23993A (en) 1990-02-09
EP0250267B1 (de) 1992-03-04

Similar Documents

Publication Publication Date Title
DE3776982D1 (de) Arzneimittel mit gesteuerter absorption.
NO884947D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk doseringsform med kontrollert frigjoerelse.
DE68907762D1 (de) Arzneizubereitung mit gesteuerter wirkstofffreisetzung und verfahren zu deren herstellung.
ATE128863T1 (de) Arzneimittelformulierungen mit verzögerter wirkstoffabgabe.
CA2021574A1 (en) Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
AU6764390A (en) Pharmaceutical granules and drug dosage units made therefrom
FI885460L (fi) Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi
DE3685392D1 (de) Galenische formen mit verzoegerter verapamil-freisetzung, deren herstellung und diese enthaltende arzneimittel.
DE69213800D1 (de) Oral anzuwendende magensaftstabile Arzneimittel mit gesteuerter Wirkstoffabgabe enthaltend Gallensäuren und deren Salze
ATE87201T1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
AU2377588A (en) Controlled absorption diltiazem formulations
DE3856258D1 (de) Verfahren zur Herstellung eines Retardpräparates, das Diltiazem in einer einzigen Tagesdosis enthält
SE8803822D0 (sv) Novel dosage form
EP0425298A3 (en) Sustained-release preparation of basic medical agent hydrochloride
ATE102480T1 (de) Multigranulaere tablette mit verzoegerter freisetzung.
ATE24664T1 (de) Arzneimittel mit programmierter abgabe, assoziierend acetylsalicylsaeure mit dihydroergotamine.
DE68900903D1 (de) Diltiazem-mikrokugeln, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen mit gesteuerter abgabe.
PT76986B (de) Neue phenylessigsaeure-derivate ihre herstellung und diese verbindungen enthaltende arzneimittel
EP0362731A3 (de) Verfahren zur Herstellung von Arzneimittelwirkstoff-Partikeln mit verbesserten Fliess-, Lager- und Formulierungseigenschaften sowie Arzneimittel, die diese Arzneimittelwirkstoff-Partikeln enthalten
JPS55133315A (en) Curing and preventive agent for digestive ulcer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition